United States: Coherus And AbbVie File Dueling Motions For Injunctive Relief Relating To Coherus's HUMIRA Biosimilar - Goodwin Procter LLP
Thursday, 29 June 2023
Our readers may recall that ten HUMIRA biosimilars have been licensed to launch, with Amgen's AMJEVITA the only one to launch to date and nine others set to launch starting in July 2023.
|
||||
You Might Like |
||||
